Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis

Ollech, Jacob; Normatov, Inessa; Peleg, Noam; Dalal, Sushila; Pekow, Joel; Micic, Dejan; Cohen, R. D.; Rubin, David T.; Sakuraba, Atsushi

doi:10.1007/s00384-020-03703-x

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Although data about the use of biosimilars in ASUC is limited, a retrospective study in 21 patients suggests similar remission rates. 38 Sequential use of ciclosporin and infliximab has been reported, but studies are generally of low quality, produced conflicting results and do not authorise its use in standard clinical practise. However, a systematic review published in 2015 and combining 10 low-quality studies (314 participants) showed pooled response rates of 62.4% (95% CI 57-68.7%) and colectomy rates at three months in 28.3% of cases (95% CI 21.7-34.5%).…”

Section: Challenge 2: Current Treatment Strategies Of Asuc Are Based mentioning

confidence: 99%

Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions

Holvoet

Lobatón²,

Hindryckx³

2021

CEG

View full text Add to dashboard Cite

Acute severe colitis is a severe complication of ulcerative colitis, affecting approximately 20% of patients. For physicians, it remains a challenging condition to treat. Current treatment algorithms have diminished the mortality associated with acute severe ulcerative colitis (ASUC), but colectomy rates remain high (approximately 30%) despite advances in therapy. Colectomy in ASUC is particularly associated with important postoperative complications and morbidity. In this review, reasons for the inability to improve care and avoid evolution to colectomy for ASUC are explored and solutions that might lead to a better management of the disease are investigated.

show abstract

Section: Challenge 2: Current Treatment Strategies Of Asuc Are Based mentioning

confidence: 99%